



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated: October 04, 2022

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,

We are herewith enclosing the press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**





Press Release

For Immediate Release

Granules India Limited Inaugurated an Overhead Water Tank at Bonthapally

Hyderabad, 4th October, 2022: Granules India Limited (GIL), a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad, inaugurated overhead tanks to facilitate a dedicated supply of potable water for residents of Bonthapally villages, located in Telangana, as part of its CSR initiative. The project was inaugurated by Dr Krishna Prasad Chigurupati, Chairman & Managing Director - GIL along with Shri. Gudem Mahipal Reddy, Member of the Telangana Legislative Assembly (MLA) from the Patancheru constituency. Mrs. Uma Devi Chigurupati, Executive Director, GIL, graced the occasion.

GIL will be inaugurating another overhead tank at Veeranagudam in the coming week. The two overhead tanks have a capacity of 150 KL at Bonthapally and 100 KL at Veeranagudam; are connected through pump assembly and piping to supply accessible drinking water to residents of both villages. Currently, the villagers are deprived of continuous drinking water supply to the households, through this initiative of Granules India Limited, over 2,000 residents from both villages will benefit. The two overhead tanks commissioned at a cost of ₹ 57 lakh will be maintained by the village panchayats.

Speaking after the commissioning of the water tank **Dr Krishna Prasad Chigurupati, Chairman & Managing Director - GIL** said, *“Potable water is a basic necessity for leading a healthy life and it’s heartening that GIL could fulfil this need of the residents of Veerannaguda and Bonthapally villages. Granules will remain committed towards the betterment of the communities who live and work around our global manufacturing units here in Bonthapally. I would like to thank Mr. Gudem Mahipal Reddy, MLA of Patancheru; Mr. K Prabhakar, Vice Chairman, ZPTC; Mrs. Saddi Praveena Vijayabhaskar Reddy, President, Mandal Praja Parishad; Mrs. Naveena Vijaya Bhaskar Reddy and Mrs. Pennaboina Mamatha, Sarpanches of Bonthapally and Veerannaguda villages respectively, for their active participation and continuous support throughout this project.”*

GIL operates two Active Pharmaceutical Ingredient manufacturing units at Bonthapally in the Sangareddy district of Telangana. The facilities offer direct and indirect employment to around 1,000 people. GIL is currently involved in a community outreach project with the surrounding villages of Bonthapally, focusing on skill development, health, water and sanitation. In the past, GIL has set up a Public Health Clinic, Donated for the construction of roads and stadium in and around the Patancheru constituency.

END



Contact:

Krishna Raghunathan Vice President – Finance and Investor Relations 040-69043573 krishna.raghunathan@granulesindia.com	Chaitanya Tummala Company Secretary 040-69043614 chaitanya.tummala@granulesindia.com
---	---

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor: This document is to provide the general background information about the Company’s activities as at the date of the release. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the Company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.